Pharmaceutical preparations containing amide derivatives that inhibit the growth of cancer cells and medicines containing the same

Abstract

The present invention relates to a pharmaceutical preparation comprising granules containing a compound of Formula 1 or a pharmaceutically acceptable salt thereof and a diluent. The pharmaceutical preparation has excellent tableting properties, friability, and mass uniformity, resulting in high productivity of the preparation. The pharmaceutical preparation has low impurity production and high stability.

Description

[Technical field]

[0001] Technical Field The present invention relates to a pharmaceutical preparation comprising an amide derivative that inhibits the growth of cancer cells and a medicine containing the same. Specifically, the present invention relates to a pharmaceutical preparation comprising a granule containing a compound of formula 1 or a pharma- ceutical acceptable salt thereof and a diluent, and a medicine containing the same.

[0002] This application claims the benefit of priority based on Korean Patent Application No. 10-2019-0132809 filed on October 24, 2019, and Korean Patent Application No. 10-2020-0137829 filed on October 22, 2020, the entire contents of which are incorporated herein by reference as part of this application. [Background technology]

[0003] Background technology Epidermal growth factor receptor (EGFR) is known to exist as four subtype receptors, EGFR / ErbB1, Her-2 / ErbB2, Her-3 / ErbB3, and Her-4 / ErbB4, and is abnormally overexpressed in most solid cancer cells. In addition, it is known that activation of the receptor by ligands activates cell signaling pathways to induce cancer cell growth, differentiation, angiogenesis, metastasis, and resistance (Wells A., Int J Biochem Cell Biol., 1999, 31, 637-643). Therefore, according to the prediction that blocking cancer cell signaling through the epidermal growth factor receptor would have an excellent anticancer effect, research is being actively conducted to develop anticancer drugs that target the epidermal growth factor receptor.

[0004] These anticancer drugs that target epidermal growth factor receptors are classified into monoclonal antibody drugs that target the extracellular domain of the receptor and small molecule drugs that target intracellular tyrosine kinases. Monoclonal antibody drugs have the advantage of showing few side effects and excellent efficacy due to selective binding to epidermal growth factor receptors. However, these drugs have the disadvantage of being expensive and having to be used in the form of injections. In contrast, small molecule drugs that target tyrosine kinases are relatively inexpensive, may be administered orally, and have excellent efficacy by acting selectively or simultaneously on epidermal growth factor receptor subtypes (EGFR, Her-2, Her-3, and Her-4).

[0005] Small molecule drugs targeting the epidermal growth factor receptor include the selective EGFR inhibitors Iressa® (chemical name: gefitinib; AstraZeneca) and Tarceva® (chemical name: erlotinib; Roche), and the dual inhibitor Tykerv® (chemical name: lapatinib; GlaxoSmithKline), which simultaneously blocks EGFR and Her-2. These are used as treatments for lung cancer and Her-2-positive advanced breast cancer, respectively, and clinical trials are underway to expand their indications to the treatment of other solid tumors.

[0006] In this regard, Korean Patent Application Publication No. 10-2008-0107294 discloses a compound of the following chemical formula 1, which selectively and effectively inhibits the growth of cancer cells and drug resistance induced by EGFR and its mutations, while having fewer side effects: [ka]

[0007] However, in relation to pharmaceutical compositions containing this compound, those skilled in the art have encountered productivity and stability problems when preparing preparations such as tablets and capsules.In particular, such compositions prepared by conventional production steps typically suffer from problems of uniform purity, predictable stability, and shelf life.Moreover, such compositions often suffer from significant capping and scuffing inconsistency during production, resulting in patients being placed in a situation where they may receive suboptimal doses.Therefore, research into pharmaceutical compositions containing this compound continues to be conducted in order to develop more suitable preparations and improve patient outcomes. [Prior art document] [Patent document] [Patent Document 1] Korean Patent Application Publication No. 10-2008-0107294 Summary of the Invention

[0008] Disclosure of the Invention technical challenges In relation to the pharmaceutical preparation comprising the above chemical formula 1, it is intended to provide a pharmaceutical preparation having high productivity due to improved tableting properties, friability and mass uniformity, and high stability due to low generation of impurities even under harsh conditions.

[0009] Resolving issues The present invention addresses the shortcomings of the prior art.

[0010] According to a first aspect of the invention, there is provided a pharmaceutical preparation comprising a granule comprising a compound of formula 1, or a pharma- ceutically acceptable salt thereof, and a diluent: [ka]

[0011] In one embodiment of the present invention, the compound of formula 1 or a pharma- ceutically acceptable salt thereof is included in the pharmaceutical preparation in an amount of 2.0% by weight or more and less than 20% by weight, based on the total weight of the pharmaceutical preparation.

[0012] In one embodiment of the present invention, the diluent is contained in the pharmaceutical composition in an amount of 20% to 50% by weight, based on the total weight of the pharmaceutical preparation.

[0013] In one embodiment of the invention, the diluent is mannitol, microcrystalline cellulose, or a mixture thereof.

[0014] In one embodiment of the present invention, the diluent is a mixture of mannitol and crystalline cellulose in a weight ratio of 0.50:1 to 3.2:1.

[0015] In one embodiment of the invention, the pharmaceutical preparation further comprises a lubricant.

[0016] In one embodiment of the invention, the lubricant is selected from the group consisting of calcium stearate, magnesium stearate, sodium lauryl sulfate, zinc stearate, sodium benzoate, and mixtures thereof.

[0017] In one embodiment of the present invention, the lubricant is included in the pharmaceutical composition in an amount of 0.5% to 1.5% by weight, based on the total weight of the pharmaceutical preparation.

[0018] According to a second aspect of the present invention, there is provided a method for preparing the aforementioned pharmaceutical preparation, comprising the steps of: 1) mixing a compound of formula 1 or a pharma- ceutically acceptable salt thereof with a pharma- ceutically acceptable excipient, followed by granulation to prepare a granule; 2) mixing the granule with a pharma-ceutically acceptable excipient, followed by adding a diluent to prepare a mixed granule; and 3) formulating the mixed granule.

[0019] According to a third aspect of the present invention, the present invention provides a method for reducing impurities in a pharmaceutical preparation comprising the compound of formula 1 by mixing granules containing the compound of formula 1 with pharma- ceutically acceptable amounts of at least two diluents in an appropriate ratio and compressing such combination into tablet form, such that the amount of such impurities including the compound of formula 2 (also referred to herein as impurity IV) will be less than 1%, preferably less than 0.5%, more preferably less than 0.2% of the total weight of the preparation. [ka]

[0020] According to a fourth aspect, the present invention provides a pharmaceutical product comprising the pharmaceutical preparation as described above packaged in a packaging material.

[0021] In one embodiment of the present invention, the material of the packaging material is selected from the group consisting of glass, high density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), polychlorotrifluoroethylene (PCTFE), cycloolefin polymer (COP), cycloolefin copolymer (COC), polyolefin (PO), aluminum (Al), and combinations thereof, and the shape of the packaging material is selected from the group consisting of a bottle, a blister, and a pouch.

[0022] In one embodiment of the invention, the packaging material includes a moisture absorbent.

[0023] In one embodiment of the present invention, the moisture absorbent is calcium oxide or silica gel.

[0024] In one embodiment of the present invention, silica gel is included in the packaging material in an amount of 2-5 g based on a 125 ml HDPE bottle.

[0025] According to a fifth aspect of the present invention, the present invention provides a method for treating cancer in a subject in need thereof.

[0026] In one embodiment of the invention, the subject has been determined to have one or more EGFR or HER2 activating mutations.

[0027] In one embodiment of the present invention, a method for treating a tumor comprises administering a therapeutically effective amount of a pharmaceutical preparation comprising granules containing a compound of the following formula 1 or a pharma- ceutically acceptable salt thereof in accordance with the present invention, and a diluent.

[0028] In one embodiment of the invention, the cancer is selected from the group consisting of lung cancer, breast cancer, colon cancer, gastric cancer, brain cancer, cervical cancer, bladder cancer, bile duct cancer, ovarian cancer, pancreatic cancer, and testicular cancer.

[0029] In one embodiment of the invention, the cancer is metastatic.

[0030] Advantageous Effects of the Invention The pharmaceutical preparation according to the present invention is a pharmaceutical preparation containing a compound of Chemical Formula 1, and by adding granules containing the compound of Chemical Formula 1 as an active ingredient and a specific diluent, the preparation has high productivity due to excellent tableting properties, friability and mass uniformity.

[0031] In addition, the present invention can provide a pharmaceutical product with low impurity production and high stability by specifying the metal salt lubricant used in the pharmaceutical preparation and packaging the pharmaceutical preparation with a specific packaging material. [Brief description of the drawings]

[0032] [Figure 1]Figure 1 is a graph showing the amount of impurity IV produced by Experimental Example 6. The tablets of Example 1 and Comparative Examples 7 and 8 were packaged in a Formpack® Dessiflex Blister (obtained from Amcor) and left under accelerated conditions of 40°C / 75% RH for 1, 2, and 4 weeks, respectively, and then measured for impurity IV of formula 2 by liquid chromatography. [Diagram 2] 2 is a graph showing the amount of impurity IV produced by Experimental Example 7. Each of the tablets of the above Examples 6 to 9 and Comparative Example 9 was packaged in a Formpack (registered trademark) Dessiflex Blister (obtained from Amcor), and HM781-36B of Comparative Example 11 was packaged in an HDPE bottle, and then these were stored at a temperature of 60° C., which is a harsh condition, for 1, 2 and 4 weeks. The impurity IV of chemical formula 2 was measured for the samples stored for the above periods according to the analytical conditions of Experimental Example 6. [Diagram 3] Figure 3 is a graph showing the yield of impurity IV according to Experimental Example 8. Each tablet according to Example 1 was packaged in either Al-Al blister, Al-PO+CaO-Al blister or HDPE bottle (five different packages, each with a polypropylene cap, including either 0.5, 2.0, 3.0, 4.0 or 5.0 g of silica gel and a polypropylene cap), TEKNILID® 1207 (Tekniplex) was used for Al-Al blister, Formpack® Dessiflex Blister (Amcor) was used for Al-PO+CaO-Al blister, and BTH-250 (Ewha Engineering) was used for HDPE bottle, and the polypropylene cap (including silica gel) was also obtained from Ewha Engineering under the trade names MH-Cap(0.5g), MH-Cap(2.0g), MH-Cap(3.0g), MH-Cap(4.0g) and MH-Cap(5.0g). The packaged products were left under 40° C. / 75% RH accelerated conditions for 1, 2, and 4 weeks, respectively, and then assayed for impurity IV of Formula 2 according to the analytical conditions of Experimental Example 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] BEST MODE FOR CARRYING OUT THE PRESENTINVENTION Hereinafter, the invention will be described in more detail.

[0034] The compound of the following formula 1 or a pharma- ceutically acceptable salt thereof is very stable by itself, but pharmaceutical preparations containing it exhibit a very unstable profile under harsh conditions. Although the instability problem has been partially improved through improvements in packaging materials, the fundamental stability of the pharmaceutical preparation has not been improved. [ka]

[0035] Therefore, in connection with the pharmaceutical preparation comprising the above chemical formula 1 in the present invention, it is intended to provide a pharmaceutical preparation having high productivity due to improved tableting properties, friability and mass uniformity, and high stability due to low formation of impurities such as the impurity having the structure of formula 2 even under harsh conditions (60° C. for 1 month).

[0036] The present invention provides a pharmaceutical preparation comprising a granule containing a compound of formula 1 or a pharma- ceutically acceptable salt thereof, and a diluent mixed with the granule.

[0037] The compound of Chemical Formula 1 (hereinafter referred to as code name HM781-36B) is a compound that selectively and effectively inhibits the growth of cancer cells and drug resistance induced by EGFR and its mutations while having few side effects, as described in Korean Patent Application Publication No. 10-2008-0107294.

[0038] The pharmaceutically acceptable salt of the compound of formula 1 may be used in the form of a pharmaceutically acceptable salt derived from inorganic or organic acid. Examples of salts may be salts with inorganic acids such as hydrochloric acid, sulfuric acid, disulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid and the like; or salts with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, succinic acid, benzoic acid, citric acid, maleic acid, malonic acid, malic acid, tartaric acid, gluconic acid, lactic acid, gestysic acid, fumaric acid, lactobionic acid, salicylic acid, phthalic acid, embonic acid, aspartic acid, glutamic acid, camsylic acid, besylic acid or acetylsalicylic acid (aspirin). In addition, the pharmaceutically acceptable salt may be in the form of a metal salt obtained by reaction with an alkali metal such as calcium, sodium, magnesium, strontium, potassium and the like.

[0039] The compound of formula 1 or a pharma- ceutically acceptable salt thereof may be included in an amount of 1.5% by weight or more and less than 25% by weight, 2.0% by weight or more and less than 20% by weight, 2.5% by weight or more and less than 20% by weight, or 5% by weight or more and less than 20% by weight, preferably 3.5% to 15% by weight, and more preferably 5% to 8% by weight, based on the total weight of the pharmaceutical preparation.

[0040] When the compound of formula 1 or a pharma- ceutically acceptable salt thereof is contained in an amount of less than 2.0% by weight, the tableting properties and dissolution rate are excellent, but the stability is very poor and impurities are rapidly produced. When the compound of formula 1 or a pharma- ceutically acceptable salt thereof is contained in an amount of 20% by weight or more, the total tablet content is reduced to a mass that is impossible to compress (less than 70 mg), thus causing the problem of tableting being impossible.

[0041] In addition, the compound of formula 1 or a pharma- ceutically acceptable salt thereof may be included in an amount of 0.1 to 100 mg, preferably 0.5 to 50 mg.

[0042] The pharmaceutical preparation may be in the form of, for example, but not limited to, a powder, tablet, pill, capsule, liquid, suspension, emulsion, syrup or granules, preferably a tablet or capsule.

[0043] The pharmaceutical preparation may further comprise diluents, binders, disintegrants and lubricants as pharma- ceutically acceptable excipients. In some embodiments, the diluent may be a combination of at least two different diluents.

[0044] In an embodiment of the present invention, the pharmaceutical preparation may include the compound of formula 1 or a pharma- ceutically acceptable salt thereof prepared in the form of granules. The granules may be prepared by mixing the compound of formula 1 or a pharma- ceutically acceptable salt thereof with a diluent, and then wet granulating it in a binder solution in which the binder is dissolved in purified water.

[0045] The diluent may be one or more selected from the group consisting of mannitol, crystalline cellulose, lactose and calcium phosphate, and may be preferably mannitol, crystalline cellulose, or a mixture thereof. In addition, the diluent may be included in an amount of 50% to 99% by weight, preferably 60% to 95% by weight, more preferably 70% to 90% by weight based on the total weight of the granule. In some embodiments, the diluent may be a combination of mannitol and crystalline cellulose.

[0046] The binder may be one or more selected from the group consisting of povidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol and carboxymethyl cellulose, preferably povidone, but is not limited thereto. The binder may be contained in the granule in an amount of 0.5% to 10% by weight, preferably 1% to 7% by weight, more preferably 2% to 5% by weight based on the total weight of the granule.

[0047] The granules may be mixed with additional diluents and then purified to prepare the pharmaceutical preparation. The diluents mixed with the granules are physically separated from the diluents used in the preparation of the granules and have different functionalities, and therefore they are separated from each other and used independently. The diluents mixed with the granules may preferably be mannitol, crystalline cellulose, or a mixture thereof, more preferably a mixture of mannitol and crystalline cellulose. The mixture of mannitol and crystalline cellulose may be a mixture of mannitol and crystalline cellulose in a weight ratio of 0.25:2-4:1.5, 0.75:1.25-3.5:1.25, or 0.50:1-3.2:1, preferably 1:1-2:1. The diluents mixed with the granules may be included in an amount of 20%-50% by weight, preferably 30%-40% by weight, based on the total weight of the pharmaceutical preparation. The choice of diluents mixed with the granules may actually affect the productivity of the pharmaceutical preparation. Specifically, by selecting the aforementioned diluents, the tableting properties and friability of the tablets can be improved, and tablets with uniform mass can be obtained.

[0048] In at least one embodiment, the diluent mixed with the granules may include two types of diluents. In some embodiments, the first type of diluent is selected from the group consisting of lactose, mannitol, calcium sulfate, sucrose, dextrose, sorbitol, maltitol, and starch, while the second type of diluent is a cellulose derivative such as microcrystalline cellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, and the like.

[0049] In at least one embodiment, the first diluent is mannitol and the second diluent is microcrystalline cellulose, and the weight ratio of mannitol to microcrystalline cellulose is in the range of 0.25:2 to 4:1.5; or 0.75:1.25 to 3.5:1.25; or preferably 0.50:1 to 3.2:1.

[0050] In some embodiments, the granules may be mixed with a disintegrant together with the aforementioned diluent, and then refined to prepare a pharmaceutical preparation. The disintegrant may be one or more selected from the group consisting of crospovidone, croscarmellose sodium, and sodium starch glycolate, preferably crospovidone, but is not limited thereto. The disintegrant may be included in an amount of 1% by weight to 10% by weight, preferably 3% by weight to 7% by weight, based on the total weight of the pharmaceutical preparation.

[0051] In some embodiments, a lubricant may be added to the pharmaceutical preparation before purification. According to one embodiment of the present invention, the lubricant may be a metal salt lubricant. The lubricant may be one or more selected from the group consisting of calcium stearate, magnesium stearate, sodium lauryl sulfate, zinc stearate, and sodium benzoate, preferably magnesium stearate. The lubricant may be included in an amount of 0.5 wt% or more and less than 5 wt%, preferably less than 2 wt%, more preferably 0.5 wt% to 1.6 wt%, based on the total weight of the pharmaceutical preparation. The compound of formula 1 or a pharma- ceutically acceptable salt thereof may have poor stability when a lubricant in the form of a metal salt is used, but the stability of the pharmaceutical preparation may be improved by including a lubricant in an amount of 0.5 wt% or more and less than 5 wt%.

[0052] In some embodiments, the present invention is substantially free (less than 1% by weight) of any acidic additive, such as acetic acid, adipic acid, citric acid, ascorbic acid, erythorbic acid, lactic acid, propionic acid, tartaric acid, fumaric acid, formic acid, oxalic acid, camsylic acid, malic acid, maleic acid, edisylic acid, palmitic acid, stearic acid or silicon dioxide.In some embodiments, the pharmaceutical preparation of the present invention contains less than 0.25% by weight of any such acidic additive.In some embodiments, the pharmaceutical preparation is free of any acidic additive.

[0053] In addition, the pharmaceutical preparation may have an outer surface coated with one type of coating base selected from the group consisting of an immediate release film-forming agent, an enteric coating base, and a sustained release coating base, in order to prevent direct contact of the pharmacologically active ingredient with human hands or skin during handling.

[0054] The immediate release film-forming agent may be one or more selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, and polyvinyl alcohol-polyethylene glycol graft polymer, the enteric coating base may be one or more selected from the group consisting of (meth)acrylic acid copolymer, hydroxypropyl methylcellulose phthalate, and cellulose acetate phthalate, and the sustained release coating base may be one or more selected from the group consisting of cellulose acetate, ethyl cellulose, and polyvinyl acetate, but is not limited thereto.

[0055] The coating base may be included in an amount of 1% by weight to 10% by weight, preferably 2% by weight to 5% by weight, based on the total weight of the pharmaceutical preparation. In a specific embodiment, the coating layer is about 0.5% by weight to about 5% by weight of the total weight of the formulation, and the coating layer has less than 18% by weight of titanium dioxide and 25% by weight or less of polyvinyl alcohol, and optionally 25% by weight or less of lactose or talc.

[0056] In some embodiments, the coating base may be a polyvinyl acetate substrate consisting solely of polyvinyl alcohol of any molecular weight, or may be contained in a copolymer, such as Kollicoat® IR (BASF, NJ, USA), or as part of a polyvinyl alcohol-based coating system such as the various film coating products available under the trade name Opadry® (Colorcon, PA, USA), such as the Opadry II® 85F series, Opadry® II 89F series, or Opadry® white.

[0057] The pharmaceutical preparation of the present invention comprises a compound of formula 1 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier, and the compound of formula 1 or a pharma- ceutically acceptable salt thereof may be present in an amount of 5% by weight or more and less than 20% by weight based on the total weight of the pharmaceutical preparation. At least one surprising observation is the improved stability, particularly the stability of the pharmaceutical preparation by inhibiting the formation of impurities under harsh conditions without affecting the tableting properties and dissolution rate. In some embodiments, the harsh conditions can include storage under accelerated conditions at 40°C and 75% RH for a period of 1, 2, 4 weeks, or 2, 3, 4, 5, or 6 months. In certain embodiments, the storage conditions can include storage under 30°C and 55% RH for a period of 6 to 12 months.

[0058] Stability in at least some embodiments of the present invention is assessed based on assay variation of more than 5% from initial value for the compound of Formula 1, or failure to meet acceptance criteria for potency when used in biological or immunological procedures for the intended application, any degradation products exceeding acceptance criteria, such as the presence of impurities, or physical attributes such as color, phase separation, caking, hardness of the final preparation, or failure to meet functional tests.

[0059] In some embodiments, the pharmaceutical preparation of the present invention is in the form of a tablet having a hardness of 4-20 kp, or preferably 6-17 kp, by using appropriate equipment.

[0060] The present invention provides a method for preparing the aforementioned pharmaceutical preparation, which includes the steps of: 1) mixing the compound of formula 1 or its pharma- ceutically acceptable salt with a pharma- ceutically acceptable excipient, then granulating to prepare granules; 2) mixing the granules with a pharma- ceutically acceptable excipient, then adding a diluent to prepare mixed granules; and 3) formulating the mixed granules. Each step of the preparation method is designated according to the contents of the aforementioned pharmaceutical preparation.

[0061] The present invention provides a pharmaceutical product in which the aforementioned pharmaceutical preparation is packaged in a packaging material. The packaging material is for protecting the preparation from light, heat, moisture and the like, and the material of the packaging material may be selected from the group consisting of glass, high density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), polychlorotrifluoroethylene (PCTFE), cycloolefin polymer (COP), cycloolefin copolymer (COC), polyolefin (PO), aluminum (Al), and combinations thereof. The packaging material may have the aforementioned materials and may be prepared in a form selected from the group consisting of bottles, blisters, and pouches. According to an embodiment of the present invention, the bottle may be a bottle made of HDPE, and the blister may be made of an upper plate comprising one or more materials selected from the group consisting of PVC, PVDC, PCTFE, PP, PE, COP, COC, PO, Al, and combinations thereof, and a lower plate comprising an Al material. The upper plate and / or the lower plate may have a single structure or a double or more structure.

[0062] The glass, HDPE, PP, PVC, PVDC, PCTFE, COP, COC, PO, and Al used in the present invention may be those commonly used in packaging of pharmaceutical products in the pharmaceutical field. For example, HDPE has a weight average molecular weight of about 50,000 to 150,000 and a viscosity of about 0.941 g / cm 3 ~0.965g / cm 3 The PP may have a weight average molecular weight of about 200,000 to 600,000, and the PVC may have a molecular weight distribution (Mw / Mn) of about 1.7 to 2.0 and a density of about 1.16 g / cm 3 ~1.35g / cm 3 PVDC may have a density of about 0.65 g / cm 3 ~1.72g / cm 3 PCTFE may have a specific gravity of about 2.12, and PO, COP and COC may have a specific gravity of about 1.02 g / cm3 It may have the following densities:

[0063] The packaging material according to the present invention may contain a moisture absorbent. The moisture absorbent has the function of increasing the stability of the pharmaceutical preparation by controlling the moisture inside the packaging material. The moisture absorbent may be used without limitation as long as it is commonly used in the relevant technical field, and preferably calcium oxide or silica gel may be used in connection with the active ingredient of the present invention. The moisture absorbent may be mixed with the material of the packaging material and applied to the packaging material in various forms. According to an embodiment of the present invention, when silica gel is used as the moisture absorbent, the silica gel may be included in the packaging material in an amount of preferably 2 to 5 g, preferably 3 to 5 g. The content of silica gel is a value set based on the packaging material for packaging a preparation containing about 480 mg of the active ingredient (HM781-36B) or a HDPE bottle with a capacity of about 125 ml. If the content of silica gel is less than 2 g, the stability of the pharmaceutical preparation inside the packaging material may decrease due to the inability to adequately control the moisture inside the packaging material, and if the content of silica gel is more than 5 g, the dissolution rate of the pharmaceutical preparation may decrease due to the effect on the moisture of the pharmaceutical preparation itself.

[0064] The present invention also provides a method for treating cancer in a subject in need thereof. In some embodiments, the method for treating cancer comprises administering a therapeutically effective amount of a pharmaceutical preparation comprising a granule comprising a compound of the following formula 1 or a pharma- ceutically acceptable salt thereof according to the present invention, and a diluent. In some embodiments, the pharmaceutical preparation is substantially free of impurity IV.

[0065] In some embodiments, the cancer is selected from the group consisting of lung cancer, breast cancer, colon cancer, gastric cancer, brain cancer, cervical cancer, bladder cancer, bile duct cancer, ovarian cancer, pancreatic cancer, and testicular cancer. In some embodiments, the cancer is metastatic.

[0066] In some embodiments, the subject is determined to have one or more EGFR or HER2 activating mutations. In some embodiments, the subject is determined to have one or more HER2 activating mutations at one or more sites selected from the group consisting of the furin-like extracellular domain, the transmembrane domain, and the kinase domain.

[0067] In some embodiments, the subject has been determined to have one or more HER2 activating mutations selected from S310F / Y, I655V, V659E, R678Q, V697L, T733I, L755X, I767M, D769H / N / Y, V773M, V777L / M, L786V, V842I, and L869R.

[0068] In some embodiments, the subject is determined to have a solid tumor with EGFR activating mutation, and the subject may or may not have NSCLC or high-grade glioblastoma.In some embodiments, the EGFR activating mutation is located in the extracellular and / or transmembrane domain, including, for example, EGFRvIII, R108K, R222C, A289T, P596L, G598V.In some embodiments, the EGFR activating mutation is located in the kinase domain, including, for example, EGFRvIII, R108K, R222C, A289T, P596L, G598V, Exon20 insertion, E709K, G719X, V742I, E746_A750del, S768I, V769M, V774M, R831C, R831H, L858R, L861Q, A864V. In some embodiments, the subject has not received chemotherapy, biologics, immunotherapy, HER2 targeted therapy, or definitive radiation therapy for the treatment of cancer.

[0069] Hereinafter, preferred examples are provided to aid in the understanding of the present invention, but the following examples are provided to facilitate the understanding of the present invention, not to limit the present invention. EXAMPLES

[0070] Example 1 Tablets containing the compound of Formula 1 (hereinafter referred to as "HM781-36B" and manufactured by Dongwoo Syntech Co., Ltd.) as an active ingredient were prepared according to the composition set forth in Table 1 below.

[0071] Specifically, HM781-36B and D-mannitol (manufactured by Roquette) were wet granulated using a high shear mixer, and the wet granulation was sieved using a No. 35 sieve (500 μm) while distributing HM781-36B with D-mannitol. Then, a suitable amount of povidone (manufactured by BASF) dissolved in purified water was added thereto to prepare the granule portion. The granule obtained through the wet granulation was sieved using a No. 20 sieve (850 μm), and then dried using a fluid bed dryer (fluid bed granulator). The above steps were repeated until the value of loss on drying was measured to obtain a result of about 0.5% or less.

[0072] The granules prepared through the above process were mixed with a mixture of mannitol and microcrystalline cellulose (manufactured by Mingtai Chemical) and crospovidone (manufactured by BASF), and then magnesium stearate (manufactured by Peter Greven, Netherlands) was added thereto for final mixing. The resulting final mixture was prepared into tablets with a hardness of about 5-10 kp by conventional methods using a tablet press (manufactured by Sejong).

[0073] Examples 2 to 5 Tablets containing HM781-36B as an active ingredient according to the composition set forth in Table 1 below were prepared in the same manner as in Example 1. [Table 1]

[0074] * Values ​​are in mg / tablet and purified water is removed during processing.

[0075] Comparative Examples 1 to 8 Tablets containing HM781-36B as an active ingredient according to the composition set forth in Table 2 below were prepared in a manner similar to that of Example 1. In Table 2 below, Pruv® sodium stearyl fumarate from JRS PHARMA, dibasic calcium phosphate from Lian yungang Debang Fine Chemical, and pregelatinized starch from Roquette were used. [Table 2]

[0076] * Values ​​are in mg / tablet and purified water is removed during processing.

[0077] Examples 6 to 9 and Comparative Examples 9 to 10 The tablets were prepared as in Example 1, and then coated with Opadary® 03F180000 to finally prepare coated tablets containing HM781-36B or a pharma-ceutically acceptable salt thereof. The compositions of Examples 6-9 and Comparative Examples 9 and 10 are shown in Table 3 below. [Table 3]

[0078] * The units of values ​​are mg / tablet, and purified water is removed during the process. HM781-36B in the above Examples 6-9 and Comparative Examples 9 and 10 was included in the amounts of 5.6 wt%, 7.7 wt%, 7.8 wt%, 7.8 wt%, 1.9 wt% and 20 wt%, respectively, based on the total weight of the pharmaceutical preparation.

[0079] Experimental Example Experimental Example 1: Evaluation of Tableting Properties of Examples 1 to 5 and Comparative Examples 1 to 6 In the above Examples 1 to 5 and Comparative Examples 1 to 6, the fluidity of the final granules before tableting (equation H=ρ T / ρ BThe Hausner ratio, calculated by B is the free settling bulk density of the powder (g / mL), and ρ T is the tapped bulk density of the powder (g / mL), as well as the capping and sticking properties of 100 tablets after the tabletting step were determined and the results are shown in Table 4 below.

[0080] The flowability of the final granules before compression is an indication of how well the tablet will flow, the better the flowability, the better the process flow, which can be confirmed by showing easy manufacturability. This is generally a pharmaceutical index and is evaluated using a value called the Hausner ratio, the closer it is to 1, the better the flowability can be indicated.

[0081] The free settling bulk density (g / mL) with Hausner ratio was calculated by weighing approximately 10 g of the final granules and placing them into a 50 mL graduated cylinder to measure the volume, and the tapped bulk density (g / mL) was calculated by measuring the free settling bulk density and tapping the graduated cylinder on the bed to measure the volume when the volume no longer decreased.

[0082] Tablet properties were tested by visually determining whether capping and sticking occurred on each of 100 tablets after each tablet was compressed with the final granulation. [Table 4]

[0083] According to Table 4 above, it can be seen that when mannitol, crystalline cellulose, or a mixture thereof was used during postmixing (Examples 1-5 and Comparative Examples 1-3), the capping or sticking phenomenon did not occur, whereas when other diluents were used (Comparative Examples 4-6), the capping or sticking phenomenon occurred. In particular, when dibasic calcium phosphate or pregelatinized starch was used (Comparative Examples 5 and 6), about 10%-30% of the capping or sticking phenomenon occurred, thereby resulting in less desirable results.

[0084] In addition, it was determined that when the diluents lactose, dibasic calcium phosphate or pregelatinized starch (Comparative Examples 4-6) and microcrystalline cellulose (Comparative Example 3) were used alone as single components, unexpected loss of flowability was observed in tablets prepared with a Hausner ratio of 1.26 or greater.

[0085] Experimental Example 2: Tableting characteristics of Examples 6 to 9 and Comparative Examples 9 and 10 The Hausner ratio, capping and sticking were confirmed in the same manner as in Experimental Example 1. [Table 5]

[0086] From the results in Table 5 above, it can be seen that all of Examples 6 to 9 and Comparative Examples 9 and 10 were measured to have a Hausner ratio of 1.26 or less, and therefore it can be confirmed that they have excellent fluidity.

[0087] In addition, after compression into tablets, capping and sticking of the tablets of Examples 6-9 and Comparative Example 9 were not visually observed. However, in the case of Comparative Example 10, it was confirmed that the total tablet mass was 80 mg, which is 40% of the weight of Example 9 containing the same HM781-36B, and therefore inadequate for the minimum amount of final granules required to prepare tablets. Comparative Example 10 is therefore a final mixture that cannot be compressed into tablets, and therefore no other evaluations were performed other than the evaluation of the granules.

[0088] From the above results, it was surprisingly observed that increasing the content of HM781-36B in the pharmaceutical preparation did not affect the tablet properties to an acceptable extent the flowability and compression of the granules.

[0089] Experimental Example 3: Evaluation of wear and tear of Examples 1-5 and Comparative Examples 1-4 For 65 tablets according to the above Examples 1-5 and Comparative Examples 1-4, the friability was measured by a friability tester (TAR200 manufactured by ERWEKA, conditions: 25 rpm, 4 minutes), and the results are shown in Table 6 below. [Table 6]

[0090] According to Example 6 above, all of the tablets according to Examples 1 to 5 and Comparative Examples 1 to 4 exhibited a friability of 1% or less, but it can be confirmed that when post-mixing was performed and mannitol, crystalline cellulose, or a mixture thereof was used (Examples 1 to 5 and Comparative Examples 1 to 3), a better friability was exhibited.

[0091] Experimental Example 4: Mass deviation test of Examples 1 to 5 and Comparative Examples 1 to 4 The mass deviation was measured for 10 tablets according to Examples 1 to 5 and Comparative Examples 1 to 4, and the results are shown in Table 7 below. [Table 7]

[0092] According to Table 7 above, when a mixture of mannitol and crystalline cellulose with a weight ratio of 1:1 to 2:1 was used as a diluent (Examples 1 to 5), it was confirmed that tablets having a uniform weight could be obtained.

[0093] Experimental Example 5: Dissolution Evaluation of Examples 6 to 9 and Comparative Example 9 The tables of Examples 6 to 9 and Comparative Example 9 above were evaluated for dissolution using the following dissolution conditions and analytical methods. The evaluation results are shown in Table 8 below.

[0094] <Dissolution Conditions> Dissolution solution: Two tablets were taken and tested in 900 mL of a buffer solution at pH 1.2. - Buffer solution at pH 1.2: 7.0 mL of HCl and water were dissolved in 2.0 g of NaCl and made up to 1000 mL. Device: Method of Apparatus 2 (paddle method) in USP <711> Dissolution Dissolution temperature: 37 ± 0.5 °C Rotation speed: 50 ± 2 rpm

[0095] <HPLC Analysis Conditions> Detector: Ultraviolet absorption spectrophotometer (measurement wavelength: 254 nm) Column: Inertsil ODS-2, 4.6 × 150 nm, 5 μm, or equivalent column Mobile phase: Acetonitrile: phosphate buffer solution (pH 2.5) = 40:60 (Phosphate buffer solution at pH 2.5: Prepared by dissolving 7.0 g of NaClO4 and 1.7 g of KH2PO4 in 1 L of purified water and adjusting the pH to 2.5 with phosphoric acid.) Analysis time: 10 minutes Column temperature: 30 °C Flow rate: 1.0 mL / min Injection volume: 50 μL

Table 8

[0096] From the results in Table 8 above, when observing the dissolution patterns of the tablets of the above Examples 6-9 and Comparative Example 9 at pH 1.2, it can be confirmed that the dissolution patterns and final dissolution rates were not affected even when the content of HM781-36B in Examples 6-9 was higher than that in Comparative Example 9.

[0097] Experimental Example 6: Stability Testing of Packaged Tablets (Example 1 and Comparative Examples 7 and 8) The tablets of Example 1 and Comparative Examples 7 and 8 were packaged in Formpack® Dessiflex Blister (obtained from Amcor) and left under accelerated conditions of 40° C. / 75% RH for 1, 2, and 4 weeks, respectively, and then measured for impurity IV represented by the following chemical formula 2 by liquid chromatography (see the analysis conditions below), and the results are shown in FIG. 1 and Table 9.

[0098] <Analysis conditions> Detector: Ultraviolet absorption spectrophotometer (measurement wavelength: 254 nm) Column: XTerra RP18, 4.6 x 150 nm, 3.5 μm, or equivalent Mobile phase: A - acetonitrile:phosphate buffer solution (pH 2.5) = 40:60 B - Acetonitrile:phosphate buffer solution (pH 2.5) = 70:30 Column temperature: 30℃ Analysis time: 45 minutes Flow rate: 1.0mL / min Injection volume: 50μL [ka] [Table 9]

[0099] According to Figure 1 and Table 9, it was determined that when magnesium stearate lubricant was used in an amount of 2 wt% or more (Comparative Example 7), the amount of impurity IV increased steadily in proportion to the time left under accelerated conditions. In addition, when another metal salt lubricant, sodium stearyl fumarate, was used in an amount of 1 wt% (Comparative Example 8), the amount of impurity IV increased steadily in proportion to the time left under accelerated conditions. Specifically, it was determined that the amount of impurity IV increased more than four-fold in the tablets of Comparative Examples 7 and 8 compared to the tablets of Example 1 when left under accelerated conditions of 40°C / 75%RH for four weeks.

[0100] From the above results, it was surprisingly observed that the type and content of lubricant present in the pharmaceutical preparation can affect the amount of impurity IV.

[0101] Experimental Example 7: Stability Tests for Packaged Tablets (Examples 6-9 and Comparative Examples 9 and 11) The stability was evaluated for the tablets of the above Examples 6 to 9 and Comparative Example 9. In addition, the stability was evaluated using HM781-36B itself as Comparative Example 11.

[0102] Specifically, each of the tablets of Examples 6 to 9 and Comparative Example 9 was packaged in a Formpack® Dessiflex Blister (obtained from Amcor), and HM781-36B of Comparative Example 11 was packaged in an HDPE bottle, and then these were stored at a temperature of 60° C., which is a harsh condition, for 1, 2, and 4 weeks. Stability evaluation was performed on the samples stored for the above periods according to the analytical conditions of Experimental Example 6. The stability evaluation was performed by measuring the impurity IV represented by the following chemical formula 2, and the results are shown in FIG. 2 and Table 10. [Table 10]

[0103] According to FIG. 2 and Table 10, Comparative Example 11, which contains only HM781-36B, showed very stable results for 4 weeks under harsh conditions.

[0104] However, it was determined that the tablets of Examples 6-9 and Comparative Example 9, which were prepared by mixing HM781-36B with a pharma- ceutically acceptable carrier, produced the impurity of formula 2 above.

[0105] Specifically, Comparative Example 9 contains HM781-36B in an amount of less than 2.0% by weight based on the total weight of the pharmaceutical preparation, and therefore it was determined that the production amount of the impurity of the above formula 2 significantly increases over time even when packaged in a stable packaging material. That is, the results showed that even if the stability is slightly increased by the packaging material, it does not improve the stability of HM781-36B itself.

[0106] However, Examples 6 to 9, which contained HM781-36B in an amount of 5% by weight or more and less than 20% by weight based on the total weight of the pharmaceutical composition, showed that the production amount of the impurity of Chemical Formula 2 above did not increase significantly.

[0107] Specifically, it was determined that when left for 4 weeks under harsh conditions at 60° C., the amount of impurity IV increased by more than 3.5 times in the tablets of Comparative Example 9 compared to the tablets of Examples 6 to 9, respectively.

[0108] From the above results, it was surprisingly observed that the content of HM781-36B in the pharmaceutical preparation can affect the amount of impurity IV.

[0109] Experimental Example 8: Stability test for each packaging material of the tablets according to Example 1 Each of the tablets according to Example 1 was packaged either in Al-Al blisters, Al-PO+CaO-Al blisters or HDPE bottles (five different packagings, each fitted with a polypropylene cap, containing either 0.5, 2.0, 3.0, 4.0 or 5.0 g of silica gel and a polypropylene cap), TEKNILID® 1207 (Tekniplex) was used for the Al-Al blisters, Formpack® Dessiflex Blister (Amcor) was used for the Al-PO+CaO-Al blisters, and BTH-250 (Ewha Engineering) was used for the HDPE bottles, and the polypropylene caps (containing silica gel) were also obtained from Ewha Engineering under the trade names MH-Cap(0.5g), MH-Cap(2.0g), MH-Cap(3.0g), MH-Cap(4.0g) and MH-Cap(5.0g). The packaged products were left under 40°C / 75%RH accelerated conditions for 1, 2, and 4 weeks, respectively, and then measured for impurity IV represented by the above chemical formula 2 by liquid chromatography (see the analysis conditions in Experimental Example 6), and the results are shown in Figure 3 and Table 11. [Table 11]

[0110] According to FIG. 3 and Table 11, it can be confirmed that when Al-PO+CaO-Al blisters containing CaO as a hygroscopic agent are used as packaging materials rather than Al-Al blisters, the increase in impurity IV decreases in proportion to the time left under accelerated conditions. In particular, in the packaging material of Al-PO+CaO-Al blisters, the increase in impurity IV decreases significantly after 2 weeks of acceleration. In addition, it can be confirmed that when HDPE bottles are used, the increase in impurity IV decreases in proportion to the time left under accelerated conditions as the amount of silica gel as a hygroscopic agent increases in the cap. In particular, the increase in impurity IV over time decreases significantly in the packaging material of HDPE bottles using caps containing 2 g or more of silica gel.

[0111] Experimental Example 9: Dissolution Testing After 4 Weeks Under Accelerated Conditions The dissolution rates of tablets left for 4 weeks under accelerated conditions according to Experimental Example 8 were measured under the dissolution and analysis conditions of Experimental Example 5, respectively, and the results are shown in Table 12. [Table 12]

[0112] According to Table 12 above, it can be seen that when HDPE packaging material with a cap containing 5.0 g of silica gel was used, the tablets left under accelerated conditions for 4 weeks had a slow initial disintegration and a lower dissolution rate. However, after a period of about 60 minutes, the difference in the dissolution rate of each tablet was not significant.

[0113] It should be appreciated that all simple modifications and variations of the present invention are within the scope of the present invention, with the specific scope of the invention being protected being defined by the appended claims.

Claims

1. Chemical formula 1: 【Chemistry 1】 or a pharma- ceutical preparation comprising a granule containing the compound of formula (I) or a pharma- ceutical acceptable salt thereof, and a diluent mixed with said granule, The diluent is a mixture of mannitol and crystalline cellulose in a weight ratio of 0.50:1 to 3.2:

1. Pharmaceutical preparations.

2. 2. The pharmaceutical preparation of claim 1, wherein the compound of formula 1 or the pharma- ceutically acceptable salt thereof is contained in the pharmaceutical preparation in an amount of 2.0% by weight or more and less than 20% by weight, based on the total weight of the pharmaceutical preparation.

3. 2. The pharmaceutical preparation of claim 1, wherein the diluent is contained in the pharmaceutical preparation in an amount of 20% to 50% by weight, based on the total weight of the pharmaceutical preparation.

4. 10. The pharmaceutical preparation of claim 1, further comprising a lubricant.

5. 5. The pharmaceutical preparation of claim 4, wherein the lubricant is selected from the group consisting of calcium stearate, magnesium stearate, sodium lauryl sulfate, zinc stearate, sodium benzoate, and mixtures thereof.

6. 5. The pharmaceutical preparation of claim 4, wherein the lubricant is present in the pharmaceutical preparation in an amount of 0.5% to 1.5% by weight, based on the total weight of the pharmaceutical preparation.

7. A method for preparing the pharmaceutical preparation of claim 1, comprising the steps of: 1) mixing the compound of formula 1 or a pharma- ceutically acceptable salt thereof with a pharma- ceutically acceptable excipient, followed by granulation to prepare granules; 2) mixing the granules with pharma- ceutically acceptable excipients and then adding a diluent to prepare a mixed granule; 3) formulating the blended granules; A method comprising:

8. 13. A pharmaceutical product, comprising the pharmaceutical preparation of claim 1 packaged in a packaging material.

9. 9. The pharmaceutical product of claim 8, wherein the material of the packaging material is selected from the group consisting of glass, high density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), polychlorotrifluoroethylene (PCTFE), cycloolefin polymer (COP), cycloolefin copolymer (COC), polyolefin (PO), aluminum (Al), and combinations thereof, and the shape of the packaging material is selected from the group consisting of a bottle, a blister, and a pouch.

10. The pharmaceutical product of claim 8 , wherein the packaging material comprises a moisture absorbent.

11. The pharmaceutical product according to claim 10, wherein the moisture absorbent is calcium oxide or silica gel.

12. The pharmaceutical product of claim 11, wherein the silica gel is contained in the packaging material in an amount of 2-5 g based on a 125 ml HDPE bottle.

13. 13. A method for improving the stability of a pharmaceutical preparation by reducing the formation of impurities comprising preparing the pharmaceutical preparation of claim 1, 1) mixing the compound of formula 1 or a pharma- ceutically acceptable salt thereof with a pharma- ceutically acceptable excipient, followed by granulation to prepare granules; 2) mixing the granules with pharma- ceutically acceptable excipients, and then adding a diluent to prepare mixed granules, the diluent being a mixture of mannitol and microcrystalline cellulose in a weight ratio of 0.50:1 to 3.2:1; 3) formulating the blended granules; A method comprising:

Images